EVALUATION OF THE NOTIFICATION PROFILE OF ADVERSE EVENTS RELATED TO CHLOROQUINE AND AZITHROMYCIN BEFORE AND DURING THE COVID-19 PANDEMIC
Keywords:
Chloroquine, Azithromycin, COVID-19, PharmacovigilanceAbstract
This study evaluated the profile of adverse event notifications related to the use of Chloroquine and Azithromycin before and during the COVID-19 pandemic. The pandemic led to massive prescribing of these drugs, even without solid scientific evidence proving their efficacy against SARS-CoV-2. Using data from the VigiMed system, adverse event notifications were analyzed for the periods from January 2018 to December 2019 (pre-pandemic) and from March 2020 to December 2021 (pandemic). The results showed a significant increase in notifications during the pandemic, highlighting the severity of adverse effects associated with the indiscriminate use of these drugs. This study emphasizes the importance of evidence-based medical practices and rigorous pharmacovigilance to avoid unnecessary risks to public health. The conclusions reinforce the need for public policies focused on health education and the prevention of self-medication, especially in scenarios of health crises.
References
CHARY, M.A. et al. COVID-19: Therapeutics and Their Toxicities. Journal of Medical Toxicology, v. 16, p. 284-294, 2020.
CHEN, N. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet, v. 395, n. 10223, p. 507-513, 2020.
DANZA, A. et al. Hidroxicloroquina no tratamento das doenças autoimunes sistêmicas. Revista Médica do Chile, v. 144, n. 2, p. 232-240. Chile, 2015.
FURTADO, H.M.R. et al. Azithromicin in addition to standard of care versus standard of care alone in the treatment of patients admitted to the hospital with severe COVID-19 in Brazil (COALITION II): a randomised clinical trial. Lancet, v. 396, p.
-967, 2020
JOHNSTON, C. et al. Hydroxychloroquine with or without azithromycin for treatment of early SARS-CoV-2 infection among high-risk outpatient adults: A randomized clinical trial. EClinical Medicine, v. 33, 2021.
SAID, S.A.A. et al. Monoterapia versus politerapia de enoxaparina e hidroxicloroquina para o tratamento de COVID-19: um ensaio clínico controlado randomizado. Pharmacy Practice, v. 21, n. 1, p. 1-7, 2023.
SANTOS, A. C. et al. Investigação original: reações adversas a medicamentos usados para a COVID-19 em cinco países da América Latina. Revista Panamericana de Saúde Pública, Washington, v. 47, n. 1, p. 45-58, 2023. Disponível em: https://doi.org/10.26633/RPSP.2023.0047. Acesso em: 28 ago. 2024.
WALKER, P.G.T. et al. The impact of COVID-19 and strategies for mitigation and suppression in low-and middle-income countries. Science, v. 369, n. 6502, p. 413-422, 2020.
Downloads
Published
Issue
Section
License
These Proceedings offer free and immediate access to their content, based on the principle that making scientific knowledge freely available to the public fosters the global democratization of knowledge.
Upon publication in the Proceedings, authors retain copyright and publication rights to their articles without restriction.
The Proceedings of the International Congress on Research, Teaching, and Extension (CIPEEX) of the Evangelical University of Goiás (UniEVANGÉLICA) adhere to the terms of the Creative Commons Attribution-NonCommercial 4.0 International license.
